Developing high-DAR ADCs with highly potent payloads such as exatecan has traditionally been a difficult chemical balancing act. Push the payload count up to a DAR of 8, and the extreme hydrophobicity of the payload often triggers severe in vitro aggregation or premature in vivo hepatic clearance — undermining the very potency gains a high DAR is meant to deliver.

A recent study published in ACS Medicinal Chemistry Letters by Aarvik Therapeutics, in collaboration with ChemVeda Life Sciences, presents what we consider a genuinely elegant chemical solution to this problem: the AV-DL055 linker-payload system. It achieves enhanced hydrophilicity while keeping linker size contained and avoiding the use of polymers altogether.

What’s New in the Architecture

To mask the hydrophobic footprint of exatecan without adding significant molecular bulk, the research team engineered a streamlined, dual-functional linker architecture built around three key elements:

• A compact backbone: a short aminoadipic acid residue serves as the core scaffold.
• A novel hydrophilic spacer: a compact 1-amino-beta-D-glucuronic acid unit is permanently appended to the side chain, replacing the need for traditional, bulky polymeric spacers like PEG or oligosarcosine.
• A cleavable release site: a second beta-glucuronidase-cleavable glucuronide unit sits at the release point, maintaining plasma stability until it encounters lysosomal glycosidases inside the target tumor cell.

Why This Approach Is Significant

By eliminating bulky PEG chains, the design avoids the immunogenicity risks associated with anti-PEG antibodies while also reducing overall molecular bulk to support better tumor penetration. Together, these design choices allow the AV-DL055 linker to enable stable, aggregation-free delivery of a highly potent DAR8 payload of unmodified exatecan — something that has historically been very difficult to achieve with conventional linker chemistry.

The preclinical results support the approach: in mouse xenograft models, a trastuzumab-DL055 construct achieved notable tumor shrinkage, outperforming the traditional tetrapeptide-linked benchmark construct.

The Broader Takeaway for ADC Developers

This work is a strong illustration of a trend we see accelerating across the ADC field: solving payload hydrophobicity and high-DAR stability through smarter, more compact linker chemistry rather than by adding bulk. The key to a successful high-DAR ADC program often comes down to custom linker synthesis — carefully balancing stability, release kinetics, and solubility for the specific payload and target in question.

How SigutLabs Can Help

At SigutLabs, we specialize in the custom synthesis of advanced, complex linkers and spacer architectures for targeted therapeutics, including work on hydrophilicity-modulating spacers and cleavable release chemistries relevant to high-DAR ADC design.

If you’re building your next-generation ADC and need a synthetic chemistry partner, contact us — our team is ready to help accelerate your pipeline.

Reference: Vasu Jammalamadaka, Jiang Liu, Sunil Bhakta, Sreenivas Velupula, Bhikshapathi Martha, Vidya Jonnalagadda, Jagath R. Junutula; Exatecan Payload-Based Antibody-Drug Conjugates with a Short Hydrophilic Cleavable Linker. ACS Med. Chem. Lett. 14 May 2026; 17 (5): 1035–1042.